Press Release: InterveXion : InterveXion Enrolls First Patient in OUTLAST, a Phase 2 Study of IXT-m200 in Methamphetamine Use Disorder

- First clinical trial of an anti-METH antibody in patients seeking treatment for methamphetamine use disorder LITTLE ROCK, ARKANSAS, USA, July 5, 2022 /⁨EINPresswire.com⁩/ -- InterveXion Therapeutics, a clinical-stage biopharmaceutical company, today ...